Scandion Oncology A/S appointed Lars Damstrup as the company?s new Chief Medical Officer (CMO). He will report to CEO Francois Martelet as a member of Scandion?s Executive Management and assume his new position after transition with current CMO Alfredo Zurlo. Lars Damstrup is a medical doctor and specialist in oncology and holds a Ph.D. from the University of Copenhagen.

He has worked with clinical development of new cancer treatments for more than 20 years in companies like Novartis, Genmab, Debiopharm and Topotarget and been Senior Medical Director in Merck Serono and Symphogen. Lars Damstrup?s immediate priority at Scandion will be the continued execution of the CORIST phase IIa trial, which studies Scandion?s lead compound SCO-101 as a combination treatment of metastatic colorectal cancer. The trial is ongoing according to plan with good patient recruitment.

It is a dose finding trial yet signals of efficacy have been observed. Topline results are still expected during the second half of 2023. Lars Damstrup will be replacing Alfredo Zurlo, who will leave Scandion once he has transitioned his tasks.